The Effect of Illness Management Skill Training Applied to Patients with Schizophrenia
Launched by NESLIHAN LOK · Mar 13, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The study examined 110 individuals aged 18-65 who were diagnosed with schizophrenia and applied to the S.U. Faculty of Medicine Mental Health and Diseases Polyclinic in the last year, according to the inclusion-exclusion criteria. A total of 50 individuals diagnosed schizophrenia were included in the study. These individuals were randomly assigned to two groups: intervention and control. Pre-test data were collected using the "Personal Information Form", "Modified Engulfment Scale", "SF 36 Quality of Life Scale" and "Illness Management and Recovery Scale-Patient Form" from the intervention ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being between the ages of 18-65,
- • Having been diagnosed with Schizophrenia for at least 6 months according to ICD-10,
- • Being registered with the Selcuk University Faculty of Medical Hospital Mental Health and Diseases Polyclinic,
- • Coming to the polyclinic for regular check-ups,
- • Getting a mild/moderate score from the Positive and Negative Syndrome Scale (PANSS),
- • Taking medication regularly,
- • Being at least literate.
- Exclusion Criteria:
- • Having an organic mental disorder or mental retardation,
- • Having a visual or hearing impairment,
- • Participating in a program similar to the intervention to be implemented.
About Neslihan Lok
Neslihan Lok is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on therapeutic areas that address unmet medical needs, Neslihan Lok collaborates with healthcare professionals, researchers, and regulatory bodies to ensure the highest standards of safety and efficacy in clinical trials. The organization prioritizes ethical practices and patient-centered approaches, striving to contribute valuable insights to the medical community and facilitate the development of new treatments that enhance the quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Konya, , Turkey
Patients applied
Trial Officials
Neslihan Lok, Prof. Dr
Study Director
Selcuk University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported